SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

Sperm Banks Lack Diverse Donors for Diverse Recipients

NEW ORLEANS — There aren’t enough sperm donors of diverse backgrounds for diverse recipients, and the racial breakdown of donors doesn’t match the U.S. male

October 21, 2023

Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus

Will we ever get an HIV vaccine? And is the oft-criticized institution that awards the Nobel Prize each year showing signs of evolution? We cover

October 5, 2023

UC San Diego’s open source AI platform revolutionizes multi-target drug discovery

Scientists at UC San Diego have developed a machine learning algorithm to simulate the time-consuming chemistry involved in the earliest phases of drug discovery, which

May 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.